David J. Katzoff - 30 Nov 2022 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ALZN	Stock Option (Right to Buy)	0	30 Nov 2022	Common Stock	1,000,000	$1.50	Direct	F1
holding	ALZN	Stock Option (Right to Buy)	400,000	30 Nov 2022	Common Stock	400,000	$1.50	Direct	F2
holding	ALZN	Stock Option (Right to Buy)	637,500	30 Nov 2022	Common Stock	850,000	$1.50	Direct	F3
holding	ALZN	Stock Option (Right to Buy)	187,500	30 Nov 2022	Common Stock	250,000	$1.50	Direct	F4
holding	ALZN	Warrants	9,000	30 Nov 2022	Common Stock	9,000	$1.50	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Mr. Katzoff was granted options, exercisable for 10 years, to purchase 1,000,000 shares of the Issuer's common stock, of which (i) 50% would vest if the Issuer's common stock closed at or above $10.00 per share for 90 consecutive trading days, and (ii) 10% would vest for each $2.00 per share increment above $10.00 per share for 90 consecutive trading days, with 100% vesting if the Issuer's common stock closed at or above $20.00 per share for 90 consecutive trading days. After November 27, 2026, the number of any unvested shares subject to the option would decrease by 25%. On November 22, 2022, the Issuer modified the vesting criteria of these options to reduce the price targets, which were previously between $10.00 and $40.00 per share, and to extend the period of time for vesting before the 25% of unvested shares subject to the option would be decreased.
F2	The stock options vest ratably over 48 months beginning on January 19, 2019.
F3	The stock options vest ratably over 16 quarters beginning on October 31, 2019.
F4	The stock options vest ratably over 16 quarters beginning on November 25, 2019.